Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers.

R Polo,X García-Albéniz, C Terán,M Morales, D Rial-Crestelo, M A Garcinuño, M García Del Toro, C Hita, J L Gómez-Sirvent, L Buzón, A Díaz de Santiago, J L Pérez Arellano, J Sanz, P Bachiller,E Martínez Alfaro,V Díaz-Brito, M Masiá, A Hernández-Torres,J Guerra, J Santos, P Arazo, L Muñoz,J R Arribas,P Martínez de Salazar,S Moreno,M A Hernán,J Del Amo,Julia Del Amo,Rosa Polo,Santiago Moreno,Juan Berenguer,Esteban Martínez,Miguel Hernán,Pablo Martínez de Salazar,Xabier García de Albéniz

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases（2022）

引用 12|浏览6

暂无评分

摘要

The target sample size was not met. Our findings are compatible with both benefit and harm of pre-exposure prophylaxis with TDF/FTC and HCQ, alone or in combination, compared with placebo.

查看译文

关键词

COVID-19,Pre-exposure prophylaxis,Randomized clinical trial,SARS-CoV-2,Tenofovir

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要